イタリアでの小腸癌治療に最適なクリニックと費用をご発見ください2026

Top Italian hospitals for small intestine cancer focus on high-volume oncology centers known as Scientific Institutes for Research, Hospitalization, and Healthcare (IRCCS). These facilities utilize multidisciplinary teams and specialized protocols like Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or minimally invasive resections to treat rare gastrointestinal malignancies.

• Specialized centers: Fondazione IRCCS Istituto Nazionale dei Tumori in Milan manages rare gastrointestinal tumors.
• High-volume surgery: Policlinico Universitario A. Gemelli in Rome performs large volumes of complex abdominal surgeries.
• Advanced technology: San Raffaele in Milan offers state-of-the-art robotic and laparoscopic suites for resections.
• Specialized techniques: Maria Cecilia Hospital provides advanced surgical oncology including specialized CRS and HIPEC procedures.

Bookimed Expert Insight: Italian surgical expertise in this field is remarkably deep. Dr. Antonio Braun has performed over 12,000 gastrointestinal interventions. Meanwhile, Prof. Marcello Deraco has successfully treated over 1,200 patients with advanced peritoneal cases. When choosing a facility, look for these individual high-volume surgical records. This level of experience often leads to more precise outcomes in rare cancer cases.

Patient Consensus: Patients emphasize choosing major university hospitals where pathology re-review is available. They note that having rapid imaging and surgery planning in one system is vital for rare cancers.

Primary surgical options in Italy focus on radical resection to achieve R0 margins. Surgeons perform segmental resections for jejunal tumors or complex pancreaticoduodenectomy for duodenal lesions. Advanced cases may receive cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Procedures follow strict European Society for Medical Oncology protocols.

• Segmental resection: Removes affected bowel sections and reattaches healthy tissue.
• Whipple procedure: Treats duodenal tumors via removal of the pancreas head and duodenum.
• Right hemicolectomy: Addresses terminal ileum tumors by removing the cecum and right colon.
• Hyperthermic chemotherapy: Combines aggressive tumor debulking with heated abdominal chemotherapy for advanced spread.

Bookimed Expert Insight: While many patients focus only on the surgery type, centralized expertise in Italy often hinges on specific unit directors. For instance, Dr. Antonio Braun at Maria Cecilia Hospital has performed over 12,000 gastrointestinal procedures. Choosing a surgeon with such high volume in laparoscopic techniques can significantly shorten your recovery time. Furthermore, Professor Marcello Deraco has treated over 1,200 patients using hyperthermic intraperitoneal chemotherapy. His experience is vital for complex cases where cancer has reached the abdominal lining.

Patient Consensus: Patients emphasize the need to confirm if a laparoscopic approach is possible to speed up healing. They often suggest bringing detailed pathology reports because surgical plans change drastically between GIST and adenocarcinoma treatments.

Multidisciplinary teams (GOM) are actively available in Italy for rare gastrointestinal cancers like small intestine malignancies. These specialized oncology groups consolidate surgical, radiological, and pathological expertise. This centralized approach ensures precise diagnostics and advanced surgical options like cytoreductive surgery and HIPEC for complex cases.

• Specialized techniques: Italian centers provide cytoreductive surgery, HIPEC, and PIPAC for advanced peritoneal cases.
• Diagnostic precision: Teams utilize PET/CT imaging and genomic sequencing to identify rare actionable mutations.
• Integrated expertise: Boards involve medical oncologists, interventional endoscopists, and radiologists in treatment planning.
• Academic leadership: Professors like Michele Reni specialize in coordinating clinical trials for gastro-esophageal cancers.

Bookimed Expert Insight: While many Italian facilities offer oncology services, peak expertise for rare small bowel tumors is often concentrated in clinics with dedicated Peritoneal Surface Malignancy units. Professor Marcello Deraco at Maria Cecilia Hospital has performed over 1,200 specialized procedures. Choosing a center with this level of high-volume surgical experience is vital for managing rare digestive tract malignancies effectively.

Patient Consensus: Patients emphasize that for rare cancers, the most critical step is confirming that a team of specialists reviews the case together. Many advise seeking second opinions at large academic hospitals to ensure the most modern pathology review and surgical coordination.

Italy serves as a European hub for treating Stage 4 peritoneal metastases. Clinics offer advanced locoregional therapies like cytoreductive surgery and heated chemotherapy. These specialized treatments target cancer within the abdominal cavity directly. Italy maintains a standardized oncology network to ensure high-volume surgical expertise.

• Cytoreductive surgery (CRS): Surgeons remove all visible tumor nodules from the abdominal lining.
• HIPEC therapy: Heated chemotherapy baths the abdomen to destroy remaining microscopic cells.
• PIPAC technology: Pressurized aerosol chemotherapy reaches deep tissues via minimally invasive laparoscopy.
• Bimodal approach: Oncologists combine local therapies with systemic intravenous chemotherapy for maximum effect.

Bookimed Expert Insight: Italian expertise in peritoneal surface malignancies is highly concentrated in specific surgical teams. Professor Marcello Deraco at Maria Cecilia Hospital has treated over 1,200 patients using CRS and HIPEC. This volume is critical because high-experience surgeons often achieve better outcomes in complex gastrointestinal cases. Patients should prioritize specialists with at least 500 completed procedures for these aggressive abdominal interventions.

Patient Consensus: Patients emphasize that eligibility depends heavily on a low tumor burden score. They recommend seeking second opinions from specialized centers to confirm if complete tumor removal is possible.

Patients in Italy enroll in experimental clinical trials for rare tumors through specialized oncology networks. The Associazione Italiana di Oncologia Medica (AIOM) portal provides a central database for research studies. Enrollment requires a referral from an oncologist at a recognized Italian reference center.

• Diagnostic review: Pathology slides must be reviewed at an Italian specialized reference center.
• Molecular profiling: Eligibility often depends on specific biomarkers or genetic mutations within the tumor.
• Reference networks: Collaboration between Italian oncology departments identifies appropriate trials for rare solid tumors.
• Expert referral: Specialist oncologists evaluate physical performance status and treatment history for strict eligibility.

Bookimed Expert Insight: Data shows that choosing specialists with research leadership roles significantly speeds up trial access. Professor Michele Reni at San Raffaele Milan coordinates national oncology guidelines and chairs clinical trials. Similarly, Professor Marcello Deraco at Maria Cecilia Hospital leads specialized units for peritoneal malignancies. These doctors often have first-hand knowledge of investigator-driven studies before they appear in public databases.

Patient Consensus: Patients note that preparing translated pathology slides and treatment history early prevents screening delays. They emphasize asking about molecularly matched or basket trials instead of just looking for stage-specific studies.

International patients can travel to Italy for treatment by securing a medical visa and hospital declaration. EU citizens enjoy visa-free entry, while non-EU patients require a Type C or D visa. You must provide proof of payment and sufficient funds for housing and medical expenses.

• Visa requirements: Non-EU patients must apply for a specific Medical Treatment Visa before travel.
• Mandatory deposit: Evidence of a 30% security deposit to the Italian facility is required.
• Legal residency: Non-EU patients must apply for a residency permit within 8 days of arrival.
• Facility standard: JCI-accredited hospitals like Maria Cecilia Hospital provide advanced surgery for international visitors.

Bookimed Expert Insight: Italian gastrointestinal specialists demonstrate exceptionally high surgical volumes that correlate with procedure safety. Dr. Antonio Braun at Maria Cecilia Hospital has performed over 12,000 gastrointestinal interventions. Prof. Marcello Deraco has treated 1,200+ patients using advanced intraperitoneal chemotherapy. Choosing such high-volume experts is vital for rare conditions like small intestine cancer.

Patient Consensus: Patients note that medical travel is most effective when seeking second opinions or rare tumor experts. It is essential to have all pathology reports and scans ready before starting the process.